BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Est. Return
22.5%
1 Year Est. Return
+22.5%
AUM
$4.46B
AUM Growth
-$732M
(-14%)
Holding
170
Top Buys
| 1 | +$50.6M | |
| 2 | +$18.9M | |
| 3 | +$17.3M | |
| 4 |
Beam Therapeutics
BEAM
|
+$17.1M |
| 5 |
Baxter International
BAX
|
+$15.6M |
Top Sells
| 1 | +$204M | |
| 2 | +$45.8M | |
| 3 | +$36.1M | |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$32.2M |
| 5 |
Tandem Diabetes Care
TNDM
|
+$28.2M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Technology | 0.01% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$51.6B
| $343M | 7.68% |
578,874
-14,310
|
|
||
2
Ionis Pharmaceuticals
IONS
$11.6B
| $237M | 5.31% |
7,853,198
-15,502
|
|
||
3
Stryker
SYK
$141B
| $211M | 4.73% |
566,597
+46,571
|
|
||
4
Intuitive Surgical
ISRG
$156B
| $211M | 4.72% |
425,746
-38,631
|
|
||
5
Alnylam Pharmaceuticals
ALNY
$63.1B
| $207M | 4.65% |
768,147
-2,121
|
|
||
6
Abbott
ABT
$222B
| $206M | 4.63% |
1,556,129
-132,531
|
|
||
7
Neurocrine Biosciences
NBIX
$13.6B
| $201M | 4.51% |
1,820,000
|
|
||
8
Vertex Pharmaceuticals
VRTX
$105B
| $200M | 4.49% |
413,071
-74,363
|
|
||
9
Boston Scientific
BSX
$145B
| $197M | 4.41% |
1,951,020
-184,275
|
|
||
10
Revolution Medicines
RVMD
$9.29B
| $155M | 3.47% |
4,374,300
-12,600
|
|
||
11
Incyte
INCY
$17B
| $127M | 2.84% |
2,091,780
-65,698
|
|
||
12
Agios Pharmaceuticals
AGIO
$2.41B
| $103M | 2.31% |
3,515,150
|
|
||
13
UnitedHealth
UNH
$323B
| $86.3M | 1.93% |
164,742
+5,029
|
|
||
14
Medtronic
MDT
$122B
| $84.3M | 1.89% |
938,355
-104,593
|
|
||
15
Scholar Rock
SRRK
$2.83B
| $80.6M | 1.81% |
2,506,890
-3,800
|
|
||
16
Becton Dickinson
BDX
$53.1B
| $78.9M | 1.77% |
344,311
+6,763
|
|
||
17
DexCom
DXCM
$26B
| $72.7M | 1.63% |
1,064,108
+19,064
|
|
||
18
Insulet
PODD
$22.3B
| $71.2M | 1.6% |
271,286
-50,631
|
|
||
19
Edwards Lifesciences
EW
$42.7B
| $70.4M | 1.58% |
971,969
-125,879
|
|
||
20
Celldex Therapeutics
CLDX
$1.76B
| $55.7M | 1.25% |
3,071,615
|
|
||
21
Penumbra
PEN
$9.9B
| $54.7M | 1.23% |
204,517
-33,536
|
|
||
22
Akero Therapeutics
AKRO
$4.3B
| $50.6M | 1.13% |
+1,250,666
|
|
||
23
Biohaven
BHVN
$1.74B
| $49.1M | 1.1% |
2,040,853
|
|
||
|
24
Beam Therapeutics
BEAM
$2.61B
| $46.8M | 1.05% |
2,395,930
+877,809
|
|
||
25
Moderna
MRNA
$10.6B
| $43M | 0.96% |
1,518,122
-82,755
|
|